496 related articles for article (PubMed ID: 31075401)
41. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
42. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
44. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
Menashe G; Borer A; Yagupsky P; Peled N; Gilad J; Fraser D; Riesenberg K; Schlaeffer F
Scand J Infect Dis; 2001; 33(3):188-93. PubMed ID: 11303808
[TBL] [Abstract][Full Text] [Related]
47. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
48. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
[TBL] [Abstract][Full Text] [Related]
49. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
[TBL] [Abstract][Full Text] [Related]
50. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
51. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
52. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
[TBL] [Abstract][Full Text] [Related]
53. Fecal carriage of extended-spectrum beta-lactamase and ampc beta-lactamase-producing enterobacteriaceae in a turkish community.
Hazirolan G; Mumcuoglu I; Altan G; Özmen BB; Aksu N; Karahan ZC
Niger J Clin Pract; 2018 Jan; 21(1):81-86. PubMed ID: 29411729
[TBL] [Abstract][Full Text] [Related]
54. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
55. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
56. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
[TBL] [Abstract][Full Text] [Related]
57. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes.
Zhang Q; Zhang W; Li Z; Bai C; Li D; Zheng S; Zhang P; Zhang S
Diagn Microbiol Infect Dis; 2017 Jul; 88(3):247-251. PubMed ID: 28434898
[TBL] [Abstract][Full Text] [Related]
58. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S
Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968
[TBL] [Abstract][Full Text] [Related]
59. [Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer].
García-Gómez M; Guío L; Hernández JL; Vilar B; Pijoán JI; Montejo JM
Rev Esp Quimioter; 2015 Oct; 28(5):256-62. PubMed ID: 26437756
[TBL] [Abstract][Full Text] [Related]
60. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
